UNSPSC 51273019: Levoxadrol hydrochloride

This classification denotes an anesthetic agent with the molecular formula C20H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3ARD9VMM81, chemically known as u-22,304a but more generally known as levoxadrol hydrochloride, which bears US NIH Compound Identifier 31785. European Medicines Agency schedules Levoxadrol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21975.

Most nations, for tariff and trade purposes, schedule levoxadrol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, LEVOXADROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levoxadrol hydrochloride bears US NLM identifiers UMLS ID C0888632 and NCI Concept Code C87595. SMILES: C1CCC(CC1)C2(OC[C@H](O2)[C@H]3CCCCN3)C4CCCCC4.CL.

UNSPSC 51273019 Levoxadrol hydrochloride is a Commodity code; however, recent state and local solicitations tagged with this code do not reflect purchases of levoxadrol specifically. Instead, the code appears in procurement records for naloxone and generic multi-source pharmaceuticals, suggesting either misclassification in source systems or broader pharmaceutical commodity grouping at the posting stage. State and local governments buying under this code designation are acquiring naloxone (opioid antagonist), safe drug deactivation systems, and generic pharmaceutical and over-the-counter products through competitive bidding processes. Issuing bodies include county health departments, state health commissions, and multistate cooperative purchasing alliances. These agencies structure buys as IFB notices (fixed-fee competitive bidding), RFIs (market intelligence for future program design), and RFPs (standing contracts to supply authorized wholesalers). Vendors must typically meet cGMP certification, Drug Supply Chain Security Act compliance, E-Verify requirements, and substantial insurance minimums ($2 million to $5 million in liability coverage). Contracts run two to three years with optional renewals.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a July 26, 2026 bid deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, proposals due March 26, 2026) to supply participating state and local facilities across multiple states including Oregon, with award execution planned for July 1, 2026. MMCAP requires vendor pricing through three authorized wholesalers and applies a 3 percent administrative fee on all purchases. The code shows pharmaceutical commodity procurement activity but limited specificity to levoxadrol itself.